ERα-mediated cell cycle progression is an important requisite for CDK4/6 inhibitor response in HR+ breast cancer.
Petrossian K, Kanaya N, Lo C, Hsu PY, Nguyen D, Yang L, Yang L, Warden C, Wu X, Pillai R, Bernal L, Huang CS, Kruper L, Yuan Y, Somlo G, Mortimer J, Chen S.
Petrossian K, et al. Among authors: kanaya n.
Oncotarget. 2018 Jun 12;9(45):27736-27751. doi: 10.18632/oncotarget.25552. eCollection 2018 Jun 12.
Oncotarget. 2018.
PMID: 29963233
Free PMC article.